Find an expert
We have many medical experts who can give opinions and guidance on health stories. Search or browse our list of experts by areas of expertise or name.
Expert Areas of expertise
Prof Andrew Spencer is the Head of our Malignant Haematology & Stem Cell Transplantation Service.
He completed his medical training in clinical and laboratory haematology in 1992. Subsequently, he was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into B-cell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London.
Andrew moved to The Alfred in 1999 where he established an independent translational research program. In parallel he established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology & Stem Cell Transplantation Service in 2007.
Most significant trial
The ALLG MM17 trial for myeloma patients who fail to respond to standard treatment. This group of patients has historically had poor survival rates. Professor Spencer’s approach exploring the use of Kyprolis and thalidomide has demonstrated very high response rates, including patients becoming minimal residual disease (MRD) negative.
Find out more about Andrew's research interests.
Simon has been a psychiatrist in the private and public sectors for over 25 years.
As the Program Director of Psychiatry at Alfred Health, Simon is responsible for the delivery of specialist and primary mental health services in the inner south of metropolitan Melbourne, and a psychiatry research centre in partnership with Monash University, known as MAPrc (Monash-Alfred Psychiatry Research Centre). As the lead agency for headspace Elsternwick since 2009 and the headspace Youth Early Psychosis Program in South-East Melbourne since 2013, the program has led a consortium of agencies in developing a youth mental health service that has been co-designed with carers and young people, and is delivered in primary care settings. He is an active member of the Royal Australian and New Zealand College of Psychiatrists and has consulted to a number of state and commonwealth advisory committees. In 2016, he will be undertaking the Williamson Community Leadership Program, run by Leadership Victoria.
Mr Jin Tee is a complex spine and brain surgeon. His surgical practice focuses on minimally invasive (MIS) and open surgical solutions for degenerative spinal disorders (including pars defect repairs), spinal tumours, spinal deformity including scoliosis, cranio-cervical junction abnormalities, and spine trauma. He also treats brain trauma, tumours, and brain fluid (CSF) flow dysfunction.
Mr Tee is heavily involved in clinical research. He concentrates on clinical outcomes of spine surgery in the fields of spine trauma, degenerative spine and spine oncology. He is involved in registry-based studies in Australia and North America to ultimately assist in improving the international quality of spine care. He is also involved internationally in spinal cord and spine column injury research. He is an active research member of the AO Spine International Oncology Study Group and a clinical researcher at the National Trauma Research Institute (NTRI). He is part of the medical advisory group (Monash Vision Group) for the Bionic Eye project in Melbourne.
Mr Tee was a medical graduate of the University of Melbourne and a Melbourne-based Australian Neurosurgery trainee. He has completed a post-graduate Doctorate of Medicine at Monash University (Melbourne). He then completed the AO Spine North America Complex Spine Surgery Fellowship at the world-renowned Vancouver Spine Institute, Vancouver General Hospital and the University of British Columbia.
Mr Vasudevan, who likes to be called Vasu, comes to us from Waikato Hospital, Hamilton, New Zealand, where he has been a vascular and endovascular surgeon for more than fifteen years. Waikato is a major referral and trauma centre for New Zealand’s mid North Island and serves a population of around 900,000.
Originally from India, Vasu has General Surgery and Vascular Surgery fellowships from the Royal Australasian College of Surgeons (RACS) and in addition he also holds a fellowship from the Royal College of Surgeons, Glasgow. Vasu has been very active with the RACS, being a member of the Board of Vascular Surgery, including Board Chair for three years. He has also been an examiner in Vascular Surgery since 2009.
Vasu’s academic interests include senior lecturer at the Waikato Clinical School, University of Auckland. He has ongoing research interests and has a number of peer reviewed publications and book chapters.
Dr Tony Walton is Deputy Director and Head of Catheter Laboratory in the Department of Cardiology. He is a clinician, interventional cardiologist who specialises in structural heart procedures.
Tony is an interventional cardiologist based at The Alfred and is an Associate Professor in Medicine at Monash University. He is an Honorary Research Fellow at The Baker Institute as well as Head of the Structural Heart Programme at the The Alfred and Director of the Cardiac Interventional Laboratories at Western Health.
His training in cardiology was at The Alfred and further postgraduate training in interventional cardiology was undertaken at Stanford University Medical Centre in the United States.
His professional interests include general and interventional cardiology with particular interests in structural heart disease and hypertension. The developing areas of percutaneous valve replacement and interventional techniques for the treatment of common conditions such as hypertension are particular interests. He has published his clinical and research work in peer reviewed manuscripts on subjects including the novel techniques of percutaneous aortic valve replacement and renal denervation for refractory hypertension
A/Prof Andrew Wei is a haematologist and the head of leukaemia research at The Alfred.
A/Prof Wei is also Chairperson AML disease group Australasian Leukaemia and Lymphoma Group, Victorian Cancer Agency Research Fellow and Adjunct Associate Professor, Australian Centre for Blood Diseases.
After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, A/Prof Wei joined The Alfred in 2008 to develop the Acute Myeloid Leukaemia (AML) research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator.
A/Prof Wei is an executive member of the ALLG Scientific Advisory Committee, and a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia. He sits on the International Steering Committee for Celgene, providing expert advice on AML.
To enhance translational research, A/Prof Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.
Most significant trial
The Alfred has made a significant impact in positioning a new class of drugs called BH3- mimetics, designed to promote cancer cell death, to treat patients with AML. The Alfred has conducted a number of clinical trials (phase 1b-3) in collaboration with Abbvie which has resulted in highly promising outcomes for elderly patients with AML. Pivotal studies are now underway to determine whether venetoclax in combination with low-dose chemotherapy will become the new standard of care for elderly AML.
Professor Glen Westall is a highly regarded specialist in the area of advanced lung disease, specifically in the fields of lung fibrosis and lung transplantation.
He is Consultant Chest and Lung Transplant Physician at The Alfred. He oversees an active research program that receives both national and international research grants. For his work in transplantation, he was the first non-American recipient of an International Career Development Award.
Prof Westall sits on a number of local, national and international academic/medical committees and is past-Chair of the Lung Advisory Committee of the Transplantation Society of Australia and New Zealand (TSANZ), the peak advisory board to the National Transplant Authority. He is Chair of the Advanced Lung Failure and Transplantation Steering Committee of the International Society of Heart and Lung Transplantation (ISHLT), the leading multidisciplinary global community for cardiothoracic transplantation. He is a foundation member of the Interstitial Lung Disease (ILD) Collaborative Research Consortium and is a chief investigator of the NHMRC Centre of Excellence in Lung Fibrosis.
His career to date has been built on the principals of clinical excellence supported by a rigorous research, teaching and academic platform.
Prof John Wilson is responsible for the treatment of patients with different lung disorders, including cystic fibrosis, asthma and pneumonia.
His research interests include the use of video-conferencing in delivering care programs, the application of electronic health records to medical systems and new pharmacological treatments in CF lung disease. He heads Monashalliance (www.monashalliance.com) which aims to implement eHealth initiatives in clinical care.
He has been elected to the Board, The Royal Australasian College of Physicians (currently President, Adult Medicine Division and Board member), a consultant to industry in Australia and overseas, a member of The Alfred Hospital Ethics Committee and has been Director of Physician Training there.